(Reuters) - The company has no plans to make the vaccine, known as ACAM2000, available outside the U.S. government's stockpile, the Food and Drug Administration reviewers also said.
Shares of Acambis were up more than 3 percent on the London Stock Exchange after news of the FDA's review.
Read more at Reuters.com Hot Stocks News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment